PE20121643A1 - Polipeptidos del factor ix modificados y usos de los mismos - Google Patents
Polipeptidos del factor ix modificados y usos de los mismosInfo
- Publication number
- PE20121643A1 PE20121643A1 PE2012000114A PE2012000114A PE20121643A1 PE 20121643 A1 PE20121643 A1 PE 20121643A1 PE 2012000114 A PE2012000114 A PE 2012000114A PE 2012000114 A PE2012000114 A PE 2012000114A PE 20121643 A1 PE20121643 A1 PE 20121643A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptide
- remains
- factor
- polypeptides
- conjugate
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 229960004222 factor ix Drugs 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23055109P | 2009-07-31 | 2009-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121643A1 true PE20121643A1 (es) | 2012-11-25 |
Family
ID=43529743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000114A PE20121643A1 (es) | 2009-07-31 | 2010-08-02 | Polipeptidos del factor ix modificados y usos de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120164130A1 (en:Method) |
| EP (1) | EP2461821A4 (en:Method) |
| JP (1) | JP2013500726A (en:Method) |
| KR (1) | KR20120060209A (en:Method) |
| CN (1) | CN102573890A (en:Method) |
| AU (1) | AU2010278721A1 (en:Method) |
| BR (1) | BR112012002072A2 (en:Method) |
| CA (1) | CA2769258A1 (en:Method) |
| CL (1) | CL2012000238A1 (en:Method) |
| CR (1) | CR20120052A (en:Method) |
| CU (3) | CU20120018A7 (en:Method) |
| DO (1) | DOP2012000030A (en:Method) |
| EA (1) | EA201290069A1 (en:Method) |
| EC (1) | ECSP12011637A (en:Method) |
| GT (1) | GT201200023A (en:Method) |
| IN (1) | IN2012DN00908A (en:Method) |
| MX (1) | MX2012001346A (en:Method) |
| PE (1) | PE20121643A1 (en:Method) |
| SG (1) | SG178119A1 (en:Method) |
| WO (1) | WO2011014890A1 (en:Method) |
| ZA (1) | ZA201200716B (en:Method) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007333049B2 (en) | 2006-12-15 | 2014-02-20 | Takeda Pharmaceutical Company Limited | Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life |
| TR201813067T4 (tr) | 2008-09-15 | 2018-09-21 | Uniqure Biopharma B V | Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem. |
| WO2011017055A2 (en) | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| NZ597600A (en) | 2009-07-27 | 2014-05-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CA2806684C (en) * | 2010-07-30 | 2020-11-17 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| JP6138052B2 (ja) | 2010-12-22 | 2017-05-31 | バクスアルタ ゲーエムベーハー | 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法 |
| BR112014014454B1 (pt) * | 2011-12-19 | 2021-03-09 | Dilafor Ab | glicosaminoglicanos não anti-coagulativos compreendendo unidade de dissacarìdo repetida e seus usos médicos |
| EP2922871B1 (en) * | 2012-11-20 | 2019-06-19 | The University of North Carolina At Chapel Hill | Methods and compositions for modified factor ix proteins |
| BR112015021364A2 (pt) * | 2013-03-13 | 2017-10-10 | Ambrx Inc | polipeptídeos de leptina canina modificados |
| TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ｉｘ融合蛋白以及其製備及使用方法 |
| WO2018022844A2 (en) | 2016-07-27 | 2018-02-01 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor ix function |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| BR112021007301A2 (pt) | 2018-10-18 | 2021-07-27 | Intellia Therapeutics, Inc. | composições e métodos para expressar fator ix |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520259A (zh) * | 2001-04-25 | 2004-08-11 | ���ݴ�ѧУ��ίԱ�� | 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法 |
| BRPI0417341A (pt) * | 2003-12-03 | 2007-04-17 | Neose Technologies Inc | fator ix glicopeguilado |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| EP2423306A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
-
2010
- 2010-08-02 KR KR1020127005191A patent/KR20120060209A/ko not_active Withdrawn
- 2010-08-02 US US13/388,288 patent/US20120164130A1/en not_active Abandoned
- 2010-08-02 PE PE2012000114A patent/PE20121643A1/es not_active Application Discontinuation
- 2010-08-02 WO PCT/US2010/044177 patent/WO2011014890A1/en not_active Ceased
- 2010-08-02 EA EA201290069A patent/EA201290069A1/ru unknown
- 2010-08-02 EP EP10805185.5A patent/EP2461821A4/en not_active Withdrawn
- 2010-08-02 SG SG2012005757A patent/SG178119A1/en unknown
- 2010-08-02 IN IN908DEN2012 patent/IN2012DN00908A/en unknown
- 2010-08-02 JP JP2012523129A patent/JP2013500726A/ja active Pending
- 2010-08-02 AU AU2010278721A patent/AU2010278721A1/en not_active Abandoned
- 2010-08-02 CA CA2769258A patent/CA2769258A1/en not_active Abandoned
- 2010-08-02 BR BR112012002072A patent/BR112012002072A2/pt not_active IP Right Cessation
- 2010-08-02 MX MX2012001346A patent/MX2012001346A/es not_active Application Discontinuation
- 2010-08-02 CN CN2010800431356A patent/CN102573890A/zh active Pending
-
2012
- 2012-01-27 DO DO2012000030A patent/DOP2012000030A/es unknown
- 2012-01-30 CR CR20120052A patent/CR20120052A/es unknown
- 2012-01-30 CU CU20120018A patent/CU20120018A7/es unknown
- 2012-01-30 EC EC2012011637A patent/ECSP12011637A/es unknown
- 2012-01-30 ZA ZA2012/00716A patent/ZA201200716B/en unknown
- 2012-01-30 GT GT201200023A patent/GT201200023A/es unknown
- 2012-01-30 CL CL2012000238A patent/CL2012000238A1/es unknown
-
2013
- 2013-04-19 CU CU2013000057A patent/CU20130057A7/es unknown
- 2013-04-19 CU CU2013000058A patent/CU20130058A7/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2461821A1 (en) | 2012-06-13 |
| EA201290069A1 (ru) | 2012-07-30 |
| CU20120018A7 (es) | 2012-06-21 |
| SG178119A1 (en) | 2012-03-29 |
| IN2012DN00908A (en:Method) | 2015-04-03 |
| CU20130058A7 (es) | 2013-06-28 |
| ZA201200716B (en) | 2013-07-31 |
| CN102573890A (zh) | 2012-07-11 |
| CA2769258A1 (en) | 2011-02-03 |
| WO2011014890A1 (en) | 2011-02-03 |
| GT201200023A (es) | 2014-01-27 |
| AU2010278721A1 (en) | 2012-02-16 |
| DOP2012000030A (es) | 2012-02-29 |
| ECSP12011637A (es) | 2012-02-29 |
| JP2013500726A (ja) | 2013-01-10 |
| US20120164130A1 (en) | 2012-06-28 |
| CL2012000238A1 (es) | 2012-10-05 |
| BR112012002072A2 (pt) | 2016-11-08 |
| EP2461821A4 (en) | 2013-07-03 |
| KR20120060209A (ko) | 2012-06-11 |
| CR20120052A (es) | 2012-06-04 |
| MX2012001346A (es) | 2012-02-17 |
| CU20130057A7 (es) | 2013-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121643A1 (es) | Polipeptidos del factor ix modificados y usos de los mismos | |
| PE20091931A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
| PE20110426A1 (es) | Polipeptidos g-csf bovinos modificados | |
| DOP2010000311A (es) | Polipeptidos modificados del factor ix y usos de los mismos | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| PE20140982A1 (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta | |
| WO2010043650A3 (en) | Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry | |
| CL2015000060A1 (es) | Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia. | |
| ES2721882T3 (es) | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas | |
| AR084053A1 (es) | Agente terapeutico que induce citotoxicidad | |
| UY33578A (es) | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| BRPI0923346A2 (pt) | Proteinas em super-helice antiparalela de cadeia simples | |
| BR112012017345A2 (pt) | "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)" | |
| CY1113869T1 (el) | Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf | |
| BR112012015461A2 (pt) | polipeptídeos de somatotropina boviina modificados e seus usos | |
| MX2017006016A (es) | Composiciones conjugadas de xten direccionadas y metodos para producir las mismas. | |
| GT200900229A (es) | Coagonistas de receptor de glucagón/glp-1 | |
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| PE20120021A1 (es) | Mutantes fgf21 | |
| CL2008003694A1 (es) | Compuestos derivados de heterociclo-2-carboxamida sustituida; composicion farmaceutica; combinacion farmaceutica; y su uso como inhibidores de dipeptidil peptidasa iv (dpp-iv) en el tratamiento del asma, epoc y rinitis alergica. | |
| AR092076A1 (es) | Proteinas homodimericas | |
| BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |